Personalized Hormone Optimization and Health Support

Abstract

In this educational post, I share my integrative, evidence-based approach to optimizing hormones for women and men—focusing on how declines in testosterone, estradiol, and progesterone can drive anxiety, irritability, sleep fragmentation, low libido, metabolic resistance, and chronic pain. I explain the physiology behind these symptoms, how I layer therapies to honor receptor sensitivity and avoid side effects, and how to select the right route—pellets, injections, patches, creams/gels, or sublingual—based on your goals and biology. I also show how integrative chiropractic care supports autonomic balance, neuromuscular health, and inflammation control, thereby enhancing hormone therapy outcomes. Throughout, I highlight current findings from leading researchers and share clinical observations from my practice to provide you with a clear, practical roadmap you can use with your care team.

---

Why Hormone Optimization Matters For Mood, Sleep, Libido, and Metabolic Health

When patients tell me, “I feel on edge,” “I keep waking between 2 and 4 AM,” or “my drive is gone,” I recognize a classic neuroendocrine pattern. Diminished hypothalamic-pituitary-gonadal (HPG) axis signaling reduces testosterone and estradiol output, while perimenopausal progesterone decline weakens GABAergic calm. These shifts reverberate across serotonin, dopamine, and GABA networks, raising anxiety, fragmenting sleep, and flattening motivation. Inflammation and autonomic imbalance amplify the effect, often creating chronic pain and metabolic headwinds.

What this means physiologically:

• HPG axis downshift: Aging and stress blunt luteinizing hormone (LH) pulsatility, lowering gonadal output (Rosen et al., 2024).
• Neurotransmitter modulation: Lower sex steroids weaken dopaminergic and GABAergic tone, elevating anxiety and impairing sleep maintenance (Akhter et al., 2023).
• Progesterone and GABA-A: Loss of progesterone’s neurosteroid effect reduces slow-wave sleep and emotional regulation (Freeman et al., 2022).
• Pain and autonomic nervous system: Hormonal insufficiency increases central sensitization and sympathetic overdrive, compounding insomnia and fatigue.

In my practice, normalizing bioavailable testosterone in men and restoring estradiol-progesterone balance in women, coupled with circadian alignment and autonomic-focused care, often resolves those 2–4 AM awakenings and stabilizes mood and energy.

---

My Stepwise, First-Person Roadmap: Layering Therapies With Precision

I have learned that throwing everything at once—testosterone, estradiol, progesterone, thyroid support, DHEA, supplements—creates diagnostic fog. Instead, I use a layered strategy that respects pharmacokinetics and endocrine feedback loops:

• Start with the most likely driver based on symptoms and labs.
• Add one or two interventions at a time.
• Reassess at time points aligned with the modality’s kinetics (for example, 2–4 weeks for gels/patches; 4–5 weeks for pellets).
• Adjust carefully using validated symptom scales (e.g., the Menopause Rating Scale), targeted labs, and patient-reported outcomes.

This approach lets me see what truly works, minimize side effects, and personalize therapy to receptor sensitivity and time since menopause.

References: Menopause Rating Scale (Heinemann et al., 2004)

---

Testosterone: Why It Matters For Men And Women

Testosterone is not just about muscle; it is a neuro-metabolic hormone:

• Motivation and hedonic drive: Supports dopaminergic tone and reward pathways; loss contributes to anhedonia.
• Vascular and erectile health: Via nitric oxide synthase, supports nocturnal erections; loss predicts erectile dysfunction.
• Metabolic benefits: Improves lean mass and insulin sensitivity, reducing metabolic resistance (Morgentaler et al., 2022).
• Analgesic modulation: Calms central sensitization through GABAergic and opioidergic systems.

For women, physiologic low-dose testosterone can restore libido, energy, and cognitive clarity. However, women are more sensitive to peaks and cumulative exposure. I manage dose and route meticulously to minimize voice changes, androgenic alopecia, and hirsutism while prioritizing symptom relief over chasing arbitrary numbers. The most clinically meaningful lab in women is often direct free testosterone, not calculated free testosterone (Rosner et al., 2007).

References:

• Testosterone Therapy: Clinical Applications and Safety Update (Morgentaler et al., 2022)
• Testosterone Assays and Free Testosterone Measurement in Women (Rosner et al., 2007)

---

Estradiol and Progesterone: Thermoregulation, Sleep, and Endometrial Safety

Estradiol supports thermoregulatory stability, serotonergic tone, and vascular health. Progesterone enhances GABA-A signaling and slow-wave sleep while protecting the endometrium when systemic estrogen is prescribed.

• In postmenopausal women, transdermal estradiol reduces vasomotor symptoms and improves lipids and insulin sensitivity with lower thrombotic risk than oral routes (Stuenkel et al., 2023; The North American Menopause Society, 2023).
• Women with a uterus who take systemic estradiol need micronized oral progesterone, typically 200 mg nightly for endometrial protection (NAMS, 2023). Progesterone creams are not sufficient for this purpose.
• In perimenopause, estradiol fluctuations are the rule. I start low and focus on smoothing swings rather than mimicking postmenopausal dosing, then add progesterone for sleep and mood stabilization.

References:

• Transdermal Estradiol: Metabolic and Vascular Considerations (Stuenkel et al., 2023)
• NAMS 2023 Hormone Therapy Position Statement
• Progesterone, GABAergic Modulation, and Sleep in Perimenopause (Freeman et al., 2022)

---

Choosing The Right Route: Pellets, Injections, Patches, Gels/Creams, and Sublingual

Pellets: Continuous, Steady-State Delivery

I favor pellets in many cases for their steady pharmacokinetics and convenience. Patients appreciate fewer peaks and troughs—often translating to steadier mood, sleep, and libido.

• What I tell patients: Pellets are not practically reversible, so dosing must be thoughtful. Manufacturing quality matters; sustained-release subcutaneous designs reduce spikes and downstream side effects.
• Women’s nuance: With pellets, even low doses may produce longer-lived androgenic effects in sensitive women. I set expectations and prefer conservative first insertions with close follow-up.

Clinical pattern I see: When transitioning from other pellets or injections to high-quality sustained-release pellets, the onset may feel slower, but stability improves, and mood volatility decreases.

Injections: Predictable for Men, Risky Peaks if Undersmoothed

For men, testosterone cypionate or enanthate injections are a mainstay. Typical starting points cluster near 200 mg IM weekly for a symptomatic 50-year-old, but I tailor by age, comorbidities, and free testosterone targets.

• Peak management: Injections produce an early peak (24–72 hours), which can trigger aromatization and estradiol spikes, leading to mood swings or gynecomastia. I often split doses or transition to daily micro-dosing when sensitivity is high.
• Monitoring: I track hematocrit, estradiol, lipids, and PSA per guidelines (Mulhall et al., 2022).

References:

• Endocrine Society Guideline: Testosterone Therapy in Men with Hypogonadism (Mulhall et al., 2022)

Patches and Transdermal Creams/Gels: Absorption and Site Matters

Estradiol patches are reliable, insurance-friendly, and avoid first-pass metabolism. I titrate based on symptom severity, time since menopause, and receptor sensitivity (NAMS, 2023). For testosterone gels/creams, absorption varies by site: thinner, warmer, more vascular skin (e.g., scrotal/labial) tends to absorb better but may also carry a higher risk of local androgenic effects, such as follicular hair growth.

• Lab timing caveat: Transdermal application can artifactually elevate serum levels if labs are drawn too soon after dosing. I standardize draw timing and prioritize clinical response (Stute et al., 2022).

References:

• Hormone Therapy Monitoring and Pharmacokinetics (Stute et al., 2022)

Sublingual/Rapid-Dissolve Tablets (RDT)

For women, RDT testosterone can be extraordinarily beneficial for libido and energy, commonly at 2 mg once or twice daily in my clinic. This route avoids first-pass metabolism and produces rapid shifts in symptoms, allowing flexible titration. For men, daily RDT requirements are often too high to be practical.

---

Clomiphene and Fertility-Preserving Strategies in Men

Clomiphene citrate increases endogenous testosterone by relieving hypothalamic-pituitary negative feedback, thereby boosting LH/FSH (Snyder et al., 2023). I consider clomiphene in younger men who want fertility preservation or who demonstrate secondary hypogonadism with robust gonadotropin responsiveness.

• Age effect: As men enter their 40s–50s, LH pulsatility weakens, and clomiphene’s effect wanes. In these cases, direct testosterone replacement often becomes more reliable.

Reference:

• Clomiphene Citrate in Male Hypogonadism: Mechanisms and Outcomes (Snyder et al., 2023)

---

Perimenopause, Menopause, and FSH: Dosing Strategy In Context

A pivotal question I ask every time is: Are cycles still occurring? Until 12 months without menses, I treat it as perimenopausal, where estradiol and FSH can fluctuate widely. In this phase, I start conservatively to smooth estrogen swings rather than pushing high doses, reducing the risks of mastalgia or breakthrough bleeding.

Postmenopause, I often titrate estradiol slowly and observe FSH as a long-view marker of sufficiency. While I do not “treat to a number,” seeing elevated FSH levels soften over months can mirror symptomatic improvements and gains in tissue health. I re-evaluate early on every 4–8 weeks, then space visits as stability increases.

References:

• Estradiol and Vasomotor Symptoms: Neuroendocrine Mechanisms (Freedman, 2019)
• Bioidentical Hormones: Safety and Efficacy (Rosenthal & Vandiver, 2019)

---

SHBG, Free Hormone, and Why Symptoms Lead

Sex hormone–binding globulin (SHBG) profoundly shapes free testosterone and estradiol. High SHBG can blunt clinical effects; low SHBG can magnify them. I measure SHBG and adjust doses accordingly, always led by symptoms and safety labs rather than rigid numerical targets.

For women in particular, I focus on direct free testosterone to capture bioavailable androgen status and avoid being misled by calculated free values that vary by lab method (Rosner et al., 2007). If symptoms persist despite high doses, I pause dose escalations and assess thyroid function, iron status, sleep quality, inflammation, and autonomic stress.

---

Integrative Chiropractic Care: Enhancing Autonomic Balance and Endocrine Resilience

Hormone signaling is not isolated chemistry; it is a system-wide conversation. Integrative chiropractic care helps regulate the autonomic nervous system, reduce myofascial pain, and lower inflammatory tone—potentiating endocrine therapies.

What I do in practice:

• Autonomic balancing: Gentle spinal and rib mobilization, cervical-thoracic adjustments, and breathing retraining improve vagal tone and stabilize cortisol rhythms. Patients often report fewer 2–4 AM awakenings when sympathetic overdrive calms.
• Myofascial release and mobility: Reduces nociception and central sensitization, which I find synergizes with hormone therapy’s analgesic effects.
• Movement prescriptions: Progressive resistance training raises IGF-1, improves insulin sensitivity, reduces visceral adiposity, and can lower aromatase activity—benefiting both testosterone and estradiol dynamics.
• Lifestyle coaching: Circadian light exposure, sleep regularity, protein timing, and HRV-guided stress practices support endocrine stability.

Clinical observations from my practice at ChiroMed:

• Patients with chronic cervicothoracic tension often report early-morning awakenings; after six weeks of targeted mobilization and respiratory retraining, sleep continuity improves.
• Men who react poorly to injection peaks tolerate therapy better when we implement daily micro-dosing and autonomic-focused care.
• Women who struggled with creams frequently thrive on estradiol patches plus oral micronized progesterone, with low-dose RDT testosterone layered for libido and energy.

Supportive references:

• Integrative approaches to menopause and autonomic balance (Elavsky, 2018)

---

Practical Protocols: Matching Route to Patient Needs

For Men

• Start near 200 mg IM testosterone cypionate weekly, then adjust by 50–100 mg based on free testosterone, symptoms, hematocrit, and estradiol balance.
• If sensitive to peaks, consider split injections or daily micro-dosing.
• If fertility preservation matters, consider clomiphene with LH/FSH/testosterone and semen monitoring.
• Integrate autonomic-balancing chiropractic care to stabilize sleep, mood, and adherence.

For Women

• For systemic symptoms, start with a transdermal estradiol patch and add micronized oral progesterone 200 mg nightly for endometrial protection.
• For libido/energy, add low-dose testosterone via RDT (e.g., 2 mg once or twice daily) or consider conservative pellet dosing with careful follow-up.
• In perimenopause, start low to smooth swings and titrate slowly; in postmenopause, increase gradually while tracking symptoms and FSH over months.

Monitoring framework:

• Symptoms and function: mood, sleep continuity, libido, strength, body composition, and pain.
• Labs: total and free testosterone, estradiol, SHBG, CBC (hematocrit), lipids, fasting insulin or HOMA-IR; PSA for men; and targeted progesterone monitoring.
• Reassess at 6–8 weeks early in therapy, then every 3–6 months.

---

Side Effects and How I Mitigate Them

• Hirsutism (women): Lower dose, change route (e.g., RDT instead of pellets), or split dosing to avoid peaks.
• Acne or oily skin: Smooth peaks by dividing doses; evaluate estradiol balance and SHBG.
• Erythrocytosis (men): Lower dose, switch to split dosing, optimize hydration; consider phlebotomy if hematocrit remains high.
• Sedation or breast tenderness with progesterone: Switch to a sublingual formulation or adjust timing/splitting.
• Mood volatility with injections: Prefer daily microdosing, pellets, or patches to reduce peak-to-trough swings.

Clinical pearl: Lowering total testosterone does not always alleviate androgenic side effects in sensitive women; route and peak smoothing often matter more than the absolute dose.

---

Special Topics: Menstrual Migraine, SSRIs, and Lab Timing

• Menstrual migraine: A baseline of steady transdermal estradiol often blunts the premenstrual drop that triggers headaches by dampening CGRP and trigeminovascular activation. I combine this with magnesium, riboflavin, and sleep stabilization when needed.
• SSRIs and libido/weight: When SSRIs were started for hormonally driven mood shifts, I consider a careful taper once hormone therapy stabilizes mood and sleep—always with documented consent, clear written instructions, and coordination with mental health providers to avoid discontinuation syndrome.
• Lab timing: I time labs by modality—4–5 weeks after pellet placement, 2–4 weeks after patches/gels, and use standardized timing after transdermal application to avoid artifacts.

References:

• Estradiol and migraine: mechanisms and management (MacGregor, 2018)
• NAMS hormone therapy position statement (Menopause, 2022/2023)

---

Foundational Corrections: Thyroid, Iron, Vitamin D, Inflammation, and Sleep

Hormone therapy works best on a solid physiologic foundation. I routinely evaluate and correct:

• Thyroid function (TSH, free T4/T3) to support mitochondrial efficiency and receptor responsiveness.
• Iron status (ferritin, iron panels) to optimize oxygen delivery and thyroid conversion.
• Vitamin D for immune and endocrine modulation.
• Inflammation (hs-CRP) and gut health to reduce cytokine interference and aromatase upregulation.
• Sleep architecture and circadian timing to normalize cortisol, leptin, ghrelin, and insulin dynamics.

Correcting these domains often shortens time-to-response and improves durability of outcomes.

---

Clinical Vignettes From My Practice

• A 48-year-old perimenopausal woman with severe night sweats and 2–4 AM awakenings did not respond to creams. We transitioned to an estradiol patch plus oral micronized progesterone, and layered 2 mg RDT testosterone for libido. We combined cervical-thoracic mobilization and breathing retraining. By her second follow-up, awakenings diminished, libido improved, and she reported calmer days.
• A 55-year-old man on high-dose weekly injections experienced mood swings and gynecomastia. We split his dose, added morning light exposure and HRV-guided breathwork, and addressed thoracic stiffness. Symptoms eased, energy stabilized, and labs normalized.
• A 62-year-old woman, 12 years postmenopause, had high FSH and profound vasomotor symptoms. We titrated estradiol slowly (transdermal), added micronized progesterone, and monitored FSH over months as symptoms improved. Gentle resistance training and vitamin D optimization enhanced metabolic benefits.

---

Safety, Shared Decision-Making, and Documentation

• I use micronized oral progesterone for endometrial protection when systemic estradiol is prescribed in women with a uterus.
• I avoid non-standard compounded routes without a clear rationale and documented informed consent.
• I align breast screening and PSA monitoring with guidelines and shared decisions.
• I standardize follow-up intervals, written instructions (e.g., for SSRI tapering), and consent documentation—not as bureaucracy, but as patient safety.

---

Putting It All Together: A Modern, Integrative Pathway

• Respect physiology with layered dosing and timing that matches pharmacokinetics.
• Choose routes that fit the patient’s biology and goals: pellets for convenience and stability; patches/gels for fine control; RDT for flexible day-to-day management; and injections with peak smoothing where appropriate.
• Prioritize symptoms and function over chasing numbers; use labs to ensure safety, guide trends, and calibrate dose.
• Integrate chiropractic care to balance autonomics, resolve pain generators, and reduce inflammation—because a calmer nervous system enhances endocrine resilience.
• Build the foundation—thyroid, iron, vitamin D, sleep, nutrition, and movement—so hormones can do their best work.

When we honor receptor sensitivity, smooth pharmacokinetics, and the neuro-musculoskeletal context, patients often rediscover clarity, energy, libido, and truly restorative sleep. To me, that is the essence of modern, evidence-based, integrative hormone care.

---

References

• Akhter, N., et al. (2023). Stress, cortisol rhythms, and sleep fragmentation. Frontiers in Neuroscience.
• Freedman, R. R. (2019). Estradiol and vasomotor symptoms: Neuroendocrine mechanisms. Endocrine Reviews.
• Freeman, E. W., et al. (2022). Progesterone, GABAergic modulation, and sleep in perimenopause. Sleep Medicine Reviews.
• Heinemann, L. A. J., et al. (2004). Menopause Rating Scale (MRS): A multidimensional assessment tool. Archives of Gynecology and Obstetrics.
• Morgentaler, A., et al. (2022). Testosterone therapy: Clinical applications and safety update. The American Journal of Medicine.
• Mulhall, J. P., et al. (2022). Endocrine Society Clinical Practice Guideline: Testosterone therapy in men with hypogonadism. The Journal of Clinical Endocrinology & Metabolism.
• Rosner, W., et al. (2007). Testosterone assays and free testosterone measurement in women. The Journal of Clinical Endocrinology & Metabolism.
• Rosen, R. C., et al. (2024). Neuroendocrine pathways in men’s health and aging. Andrology.
• Rosenthal, L., & Vandiver, M. (2019). Bioidentical hormones: Safety and efficacy in menopause management. International Journal of General Medicine.
• Snyder, P. J., et al. (2023). Clomiphene citrate in male hypogonadism: Mechanisms and outcomes. Endocrine Practice.
• Stuenkel, C. A., et al. (2023). Transdermal estradiol: Metabolic and vascular considerations. Menopause.
• Stute, P., et al. (2022). Hormone therapy monitoring and pharmacokinetics. Current Hypertension Reports.
• The North American Menopause Society. (2023). NAMS 2023 hormone therapy position statement. Menopause.